Suppr超能文献

澳大利亚塔斯马尼亚州糖尿病患者与非糖尿病患者发生重大并发症的费用。

Costs of major complications in people with and without diabetes in Tasmania, Australia.

作者信息

Dinh Ngan T T, de Graaff Barbara, Campbell Julie A, Jose Matthew D, John Burgess, Saunder Timothy, Kitsos Alex, Wiggins Nadine, Palmer Andrew J

机构信息

Health Economics Research Group, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia; and Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen University, Thai Nguyen, Vietnam.

Health Economics Research Group, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia.

出版信息

Aust Health Rev. 2022 Dec;46(6):667-678. doi: 10.1071/AH22180.

Abstract

Objective We set out to estimate healthcare costs of diabetes complications in the year of first occurrence and the second year, and to quantify the incremental costs of diabetes versus non-diabetes related to each complication. Methods In this cohort study, people with diabetes (n  = 45 378) and their age/sex propensity score matched controls (n  = 90 756) were identified from a linked dataset in Tasmania, Australia between 2004 and 2017. Direct costs (including hospital, emergency room visits and pathology costs) were calculated from the healthcare system perspective and expressed in 2020 Australian dollars. The average-per-patient costs and the incremental costs in people with diabetes were calculated for each complication. Results First-year costs when the complications occurred were: dialysis $78 152 (95% CI 71 095, 85 858), lower extremity amputations $63 575 (58 290, 68 688), kidney transplant $48 487 (33 862, 68 283), non-fatal myocardial infarction $30 827 (29 558, 32 197), foot ulcer/gangrene $29 803 (27 183, 32 675), ischaemic heart disease $29 160 (26 962, 31 457), non-fatal stroke $27 782 (26 285, 29 354), heart failure $27 379 (25 968, 28 966), kidney failure $24 904 (19 799, 32 557), angina pectoris $18 430 (17 147, 19 791), neuropathy $15 637 (14 265, 17 108), nephropathy $15 133 (12 285, 18 595), retinopathy $14 775 (11 798, 19 199), transient ischaemic attack $13 905 (12 529, 15 536), vitreous hemorrhage $13 405 (10 241, 17 321), and blindness/low vision $12 941 (8164, 19 080). The second-year costs ranged from 16% (ischaemic heart disease) to 74% (dialysis) of first-year costs. Complication costs were 109-275% higher than in people without diabetes. Conclusions Diabetes complications are costly, and the costs are higher in people with diabetes than without diabetes. Our results can be used to populate diabetes simulation models and will support policy analyses to reduce the burden of diabetes.

摘要

目的 我们旨在估算糖尿病并发症首次发生当年及次年的医疗费用,并量化糖尿病相对于非糖尿病在每种并发症方面的增量成本。方法 在这项队列研究中,从澳大利亚塔斯马尼亚州2004年至2017年的一个关联数据集中识别出糖尿病患者(n = 45378)及其年龄/性别倾向评分匹配的对照者(n = 90756)。从医疗保健系统角度计算直接成本(包括住院、急诊就诊和病理检查成本),并以2020年澳元表示。计算每种并发症在糖尿病患者中的人均成本和增量成本。结果 并发症发生时的首年成本为:透析78152澳元(95%可信区间71095,85858),下肢截肢63575澳元(58290,68688),肾移植48487澳元(33862,68283),非致命性心肌梗死30827澳元(29558,32197),足部溃疡/坏疽29803澳元(27183,32675),缺血性心脏病29160澳元(26962,31457),非致命性中风27782澳元(26285,29354),心力衰竭27379澳元(25968,28966),肾衰竭24904澳元(19799,32557),心绞痛18430澳元(17147,19791),神经病变15637澳元(14265,17108),肾病15133澳元(12285,18595),视网膜病变14775澳元(11798,19199),短暂性脑缺血发作13905澳元(12529,15536),玻璃体积血13405澳元(10241,17321),失明/视力低下12941澳元(8164,19080)。次年成本为首年成本的16%(缺血性心脏病)至74%(透析)。并发症成本比无糖尿病者高109% - 275%。结论 糖尿病并发症成本高昂,糖尿病患者的成本高于非糖尿病患者。我们的结果可用于填充糖尿病模拟模型,并将支持政策分析以减轻糖尿病负担。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验